Aptose Biosciences Inc.

NASDAQ:APTO

0.25 (USD) • At close December 24, 2024
Bedrijfsnaam Aptose Biosciences Inc.
Symbool APTO
Munteenheid USD
Prijs 0.25
Beurswaarde 14,880,300
Dividendpercentage 0%
52-weken bereik 0.13 - 2.68
Industrie Biotechnology
Sector Healthcare
CEO Dr. William G. Rice Ph.D.
Website https://www.aptose.com

An error occurred while fetching data.

Over Aptose Biosciences Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia

Vergelijkbare Aandelen

iCAD, Inc. logo

iCAD, Inc.

ICAD

1.78 USD

Axcella Health Inc. logo

Axcella Health Inc.

AXLA

4.58 USD

DURECT Corporation logo

DURECT Corporation

DRRX

0.97 USD

Ardelyx, Inc. logo

Ardelyx, Inc.

ARDX

4.64 USD

Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

TRVI

4 USD

Aeglea BioTherapeutics, Inc. logo

Aeglea BioTherapeutics, Inc.

AGLE

12.01 USD

LAVA Therapeutics N.V. logo

LAVA Therapeutics N.V.

LVTX

0.975 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)